Researchers used fine mapping and other approaches to prioritize proposed coding and non-coding causal variants at rheumatoid arthritis- and type 1 diabetes-linked loci.
These differentially variable positions appear to implicate stress response in rheumatoid arthritis development and possibly in other autoimmune conditions.
According to Myriad, a similar deal is in the works with the pharmacy benefit management services provider for its GeneSight pharmacogenetic test.
The company had total revenues of $193.5 million during the quarter, driven by continued increases in revenue and test volume for its more recently launched and acquired tests.
HTG Molecular will provide Firalis with technology and components to support its commercialization of a rheumatoid arthritis theranostic assay.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
The partners are initially planning to make searchable whole-genome data and EMRs from more than 1,000 rheumatoid arthritis patients accessible to trial developers.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
The deal joins Metabolon's metabolomics expertise with InnVentis' big data and machine learning platform.
Contractor Palmetto GBA issued a draft local coverage determination proposing ending coverage of the test based on factors including a recent critical study.
NPR reports that with medical data being big business, some companies want to get patients involved.
The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.
In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.